- Home
- GHG vs YMAB Comparison
GHG vs YMAB Comparison
Compare GHG & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHG
- YMAB
- Stock Information
- Founded
- GHG 2004
- YMAB 2015
- Country
- GHG China
- YMAB United States
- Employees
- GHG N/A
- YMAB N/A
- Industry
- GHG Hotels/Resorts
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GHG Consumer Discretionary
- YMAB Health Care
- Exchange
- GHG Nasdaq
- YMAB Nasdaq
- Market Cap
- GHG 279.2M
- YMAB 270.5M
- IPO Year
- GHG 2018
- YMAB 2018
- Fundamental
- Price
- GHG $2.52
- YMAB $4.95
- Analyst Decision
- GHG
- YMAB Buy
- Analyst Count
- GHG 0
- YMAB 11
- Target Price
- GHG N/A
- YMAB $19.64
- AVG Volume (30 Days)
- GHG 27.0K
- YMAB 333.1K
- Earning Date
- GHG 03-25-2025
- YMAB 03-04-2025
- Dividend Yield
- GHG 3.19%
- YMAB N/A
- EPS Growth
- GHG N/A
- YMAB N/A
- EPS
- GHG 0.28
- YMAB N/A
- Revenue
- GHG $201,166,731.00
- YMAB $87,685,000.00
- Revenue This Year
- GHG N/A
- YMAB $20.07
- Revenue Next Year
- GHG $8.78
- YMAB $8.76
- P/E Ratio
- GHG $9.74
- YMAB N/A
- Revenue Growth
- GHG N/A
- YMAB 3.38
- 52 Week Low
- GHG $2.31
- YMAB $4.25
- 52 Week High
- GHG $3.48
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- GHG 42.71
- YMAB 39.96
- Support Level
- GHG $2.44
- YMAB $4.45
- Resistance Level
- GHG $2.83
- YMAB $4.97
- Average True Range (ATR)
- GHG 0.13
- YMAB 0.35
- MACD
- GHG -0.01
- YMAB 0.05
- Stochastic Oscillator
- GHG 20.77
- YMAB 55.45
About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.